Skip to content

Repligen RGEN Accounts Payable

Accounts Payable at other companies

TEC
Bio-TechneTECH
$23.49M-25.8%
Revvity logo
RevvityRVTY
$169.68M-4.7%
Danaher logo
DanaherDHR
$1.79B+3.9%
Agilent Technologies logo
Agilent TechnologiesA
$615M+19.0%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$133.1M-3.5%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$133.95M-10.3%

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's accounts payable?
Repligen (RGEN) reported accounts payable of $34.66M in Q1 2026.
How has Repligen's accounts payable changed year-over-year?
Repligen's accounts payable increased by 28.7% year-over-year, from $26.94M to $34.66M.
What is the long-term trend for Repligen's accounts payable?
Over 5 years (2020 to 2025), Repligen's accounts payable has grown at a 12.2% compound annual growth rate (CAGR), from $16.88M to $30.01M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.